Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Genmab Yönetim

Yönetim kriter kontrolleri 3/4

Genmab's CEO'su Jan G.J. de Winkel, Jun2010 tarihinde atandı, in görev süresi 14.33 yıldır. in toplam yıllık tazminatı DKK 44.30M olup, şirket hissesi ve opsiyonları dahil olmak üzere 20.8% maaş ve 79.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.99% ine doğrudan sahiptir ve bu hisseler DKK 1.02B değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 7.3 yıl ve 7.6 yıldır.

Anahtar bilgiler

Jan G.J. de Winkel

İcra Kurulu Başkanı

DKK 44.3m

Toplam tazminat

CEO maaş yüzdesi	20.8%
CEO görev süresi	14.3yrs
CEO sahipliği	1.0%
Yönetim ortalama görev süresi	7.3yrs
Yönetim Kurulu ortalama görev süresi	7.6yrs

Son yönetim güncellemeleri

We Think Genmab A/S' (CPH:GMAB) CEO Compensation Package Needs To Be Put Under A Microscope

Mar 07

Recent updates

We Think Genmab A/S' (CPH:GMAB) CEO Compensation Package Needs To Be Put Under A Microscope

Mar 07

Genmab's (CPH:GMAB) Conservative Accounting Might Explain Soft Earnings

Feb 21

Is Genmab A/S (CPH:GMAB) Trading At A 50% Discount?

Nov 13

Is Now The Time To Put Genmab (CPH:GMAB) On Your Watchlist?

Jun 19

Is There An Opportunity With Genmab A/S' (CPH:GMAB) 44% Undervaluation?

May 29

With EPS Growth And More, Genmab (CPH:GMAB) Makes An Interesting Case

Mar 18

Genmab A/S (CPH:GMAB) Shares Could Be 50% Below Their Intrinsic Value Estimate

Feb 27

Here's Why We Think Genmab (CPH:GMAB) Is Well Worth Watching

Dec 17

CEO Tazminat Analizi

Jan G.J. de Winkel'un ücretlendirmesi Genmab'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	DKK 6b
Mar 31 2024	n/a	n/a	DKK 5b
Dec 31 2023	DKK 44m	DKK 9m	DKK 4b
Sep 30 2023	n/a	n/a	DKK 4b
Jun 30 2023	n/a	n/a	DKK 5b
Mar 31 2023	n/a	n/a	DKK 5b
Dec 31 2022	DKK 42m	DKK 9m	DKK 5b
Sep 30 2022	n/a	n/a	DKK 6b
Jun 30 2022	n/a	n/a	DKK 4b
Mar 31 2022	n/a	n/a	DKK 2b
Dec 31 2021	DKK 38m	DKK 8m	DKK 3b
Sep 30 2021	n/a	n/a	DKK 3b
Jun 30 2021	n/a	n/a	DKK 3b
Mar 31 2021	n/a	n/a	DKK 6b
Dec 31 2020	DKK 37m	DKK 7m	DKK 5b
Sep 30 2020	n/a	n/a	DKK 6b
Jun 30 2020	n/a	n/a	DKK 6b
Mar 31 2020	n/a	n/a	DKK 2b
Dec 31 2019	DKK 35m	DKK 7m	DKK 2b
Sep 30 2019	n/a	n/a	DKK 2b
Jun 30 2019	n/a	n/a	DKK 1b
Mar 31 2019	n/a	n/a	DKK 1b
Dec 31 2018	DKK 28m	DKK 7m	DKK 1b
Sep 30 2018	n/a	n/a	DKK 1b
Jun 30 2018	n/a	n/a	DKK 1b
Mar 31 2018	n/a	n/a	DKK 1b
Dec 31 2017	DKK 27m	DKK 7m	DKK 1b

Tazminat ve Piyasa: Jan G.J. 'nin toplam tazminatı ($USD 6.57M ), Danish pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 3.69M ).

Tazminat ve Kazançlar: Jan G.J. 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Jan G.J. de Winkel (63 yo)

14.3yrs

Görev süresi

DKK 44,300,000

Tazminat

Dr. Jan G.J. van de Winkel, Ph.D. was Independent Director of HOOKIPA Pharma Inc. from 2023 until August 30, 2024 and served as Chairman of the Board since 2024 August 30, 2024. Dr. Winkel served as a Memb...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jan G.J. de Winkel	Co-Founder	14.3yrs	DKK 44.30m	0.99% DKK 985.9m
Anthony Pagano	Executive VP & CFO	4.6yrs	DKK 19.60m	0.011% DKK 11.0m
Anthony Mancini	Executive VP & COO	4.6yrs	DKK 21.80m	0.0045% DKK 4.5m
Birgitte Stephensen	Executive VP & Chief Legal Officer	14.8yrs	DKK 10.10m	Veri yok
Christopher Cozic	Executive VP & Chief People Officer	6.9yrs	DKK 13.20m	Veri yok
Martine van Vugt	Executive VP & Chief Strategy Officer	10.8yrs	DKK 8.90m	Veri yok
Martin Schultz	Senior Director of Clinical Operations & Non-Independent Director	no data	DKK 800.00k	0.00061% DKK 605.7k
Judith Klimovsky	Executive VP & Chief Development Officer	7.7yrs	DKK 21.70m	0.014% DKK 13.7m
Tahamtan Ahmadi	Executive VP	3.6yrs	DKK 19.80m	0.0049% DKK 4.8m
Mijke Zachariasse	Senior Director	no data	DKK 1.10m	0.00083% DKK 824.1k
Takahiro Hamatani	Senior Director of Finance Japan & Non-Independent Director	no data	DKK 800.00k	0.00013% DKK 129.1k
Andrew Carlsen	Senior Director	no data	Veri yok	Veri yok

7.3yrs

Ortalama Görev Süresi

51yo

Ortalama Yaş

Deneyimli Yönetim: GMAB 'un yönetim ekibi deneyimli ve deneyimlidir ( 7.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Martin Schultz	Senior Director of Clinical Operations & Non-Independent Director	2.8yrs	DKK 800.00k	0.00061% DKK 605.7k
Mijke Zachariasse	Senior Director	5.6yrs	DKK 1.10m	0.00083% DKK 824.1k
Takahiro Hamatani	Senior Director of Finance Japan & Non-Independent Director	2.8yrs	DKK 800.00k	0.00013% DKK 129.1k
Anders Pedersen	Non-Independent Director	20.9yrs	DKK 1.70m	0.011% DKK 11.4m
Elizabeth O'Farrell	Independent Director	2.6yrs	DKK 1.90m	Veri yok
Deirdre Connelly	Independent Chairman of the Board	7.6yrs	DKK 2.80m	0.0091% DKK 9.0m
Rolf Hoffmann	Independent Director	7.6yrs	DKK 1.50m	0.0053% DKK 5.3m
Pernille Erenbjerg	Independent Deputy Chairman	9.8yrs	DKK 2.10m	0.0076% DKK 7.6m
Paolo Paoletti	Independent Director	9.8yrs	DKK 1.50m	0.0033% DKK 3.3m

7.6yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: GMAB 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.6 yıldır).

Genmab Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Genmab A/S Announces Executive Changes

Co-Founder exercised options to buy kr.45m worth of stock.

Non-Independent Director recently sold kr.3.8m worth of stock

Genmab A/S Announces Executive Changes

We Think Genmab A/S' (CPH:GMAB) CEO Compensation Package Needs To Be Put Under A Microscope

Executive VP & CFO recently sold kr.22m worth of stock

Recent updates

The Price Is Right For Genmab A/S (CPH:GMAB)

Genmab Announces New Data from the Phase 1/2 Study Of Rinatabart Sesutecan (Rina-S), an Investigational Folate Receptor-Alpha (FRa)-Targeted, Topo1 Antibody-Drug Conjugate

We Think Genmab's (CPH:GMAB) Solid Earnings Are Understated

Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Executive Changes

Co-Founder exercised options to buy kr.45m worth of stock.

Second quarter 2024 earnings released: EPS: kr.21.85 (vs kr.20.46 in 2Q 2023)

Consensus EPS estimates fall by 15%

Genmab A/S Takes Full Control of Acasunlimab Development Program

Consensus EPS estimates increase by 14%

Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY

Non-Independent Director recently sold kr.3.8m worth of stock

Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma

Genmab A/S (CPSE:GMAB) completed the acquisition of ProfoundBio, Inc.

Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association (Eha) Congress

Consensus EPS estimates fall by 11%

First quarter 2024 earnings released: EPS: kr.20.29 (vs kr.3.46 in 1Q 2023)

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S' (CPH:GMAB) Price In Tune With Earnings

Genmab A/S Announces Executive Changes

We Think Genmab A/S' (CPH:GMAB) CEO Compensation Package Needs To Be Put Under A Microscope

Executive VP & CFO recently sold kr.22m worth of stock

Executive VP & CFO exercised options to buy kr.22m worth of stock.

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Genmab's (CPH:GMAB) Conservative Accounting Might Explain Soft Earnings

Full year 2023 earnings: EPS misses analyst expectations

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc

Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Is Genmab A/S (CPH:GMAB) Trading At A 50% Discount?

Genmab A/S Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: EPS: kr.32.60 (vs kr.39.55 in 3Q 2022)

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Investor sentiment deteriorates as stock falls 16%

Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell Lymphoma

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’

Is Now The Time To Put Genmab (CPH:GMAB) On Your Watchlist?

Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023

Co-Founder recently sold kr.58m worth of stock

Is There An Opportunity With Genmab A/S' (CPH:GMAB) 44% Undervaluation?

U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Genmab A/S Provides Earnings Guidance for 2023

First quarter 2023 earnings released: EPS: kr.3.46 (vs kr.7.10 in 1Q 2022)

Independent Chairman of the Board recently bought kr.796k worth of stock

With EPS Growth And More, Genmab (CPH:GMAB) Makes An Interesting Case

Genmab A/S (CPH:GMAB) Shares Could Be 50% Below Their Intrinsic Value Estimate

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Genmab A/S Announces Submission of Japan New Drug Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Here's Why We Think Genmab (CPH:GMAB) Is Well Worth Watching

Co-Founder recently sold kr.57m worth of stock

Genmab A/S Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting

Genmab A/S to Report Nine Months, 2023 Results on Nov 07, 2023

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat